India Confronts Nipah Virus Outbreak in West Bengal Amid Complex Infectious Disease Landscape
KOLKATA, 27 January 2026 – Health authorities in India are racing to contain a new outbreak of the deadly Nipah virus in the eastern state of West Bengal, with five confirmed infections reported as of 23 January 2026. The outbreak near Kolkata has prompted urgent public health measures, including the quarantine of nearly 100 contacts, while the country continues to manage other infectious disease threats including COVID-19, Zika, and Chandipura virus.
Current Nipah Outbreak Details
The current cluster began in Barasat, a town approximately 25 kilometres from Kolkata, where two nurses working at a private hospital developed symptoms after caring for a patient. According to the West Bengal health department, three additional healthcare workers—a doctor, another nurse, and a health worker—have since tested positive. All five patients have been transferred to the infectious diseases hospital in Beleghata, eastern Kolkata, with one female patient reported to be in critical condition.
Contact tracing and surveillance efforts are underway, with health officials reporting that 180 people have been tested and 20 high-risk contacts quarantined. The Ministry of Health and Family Welfare has issued advisories to all Indian states urging strengthened surveillance, particularly for Acute Encephalitis Syndrome (AES) in patients with travel or contact history linked to West Bengal.
Nipah Virus: Key Facts and Historical Context
| Aspect | Details |
|---|---|
| First Identified | 1999 during outbreak in Malaysia and Singapore |
| Natural Reservoir | Fruit bats (Pteropus species) |
| Transmission Routes | Direct contact with infected bats/animals, contaminated food, human-to-human contact |
| Fatality Rate | 40-75% (varies by outbreak) |
| Treatment/Vaccine | No specific treatment or approved vaccine; supportive care only |
| Previous Indian Outbreaks | West Bengal (2001, 2007), Kerala (9 outbreaks since 2018) |
Symptoms and Clinical Presentation
Nipah virus infection typically begins with non-specific flu-like symptoms including fever, headache, muscle pain and fatigue. Respiratory symptoms such as cough and shortness of breath may develop. The most serious complication is encephalitis (brain inflammation), which can lead to confusion, altered consciousness, seizures, or coma, usually appearing several days to weeks after initial symptoms. The incubation period ranges from 4 to 21 days, though longer periods have been reported.
India’s Broader Infectious Disease Context
While addressing the Nipah outbreak, India continues to manage multiple other infectious disease threats:
COVID-19: India is witnessing a resurgence with over 6,000 active cases and six deaths reported in the last 24 hours according to recent reports. Kerala, Gujarat, West Bengal, and Delhi are among the most affected states. The country has reported approximately 45 million cases and 534,000 deaths since the pandemic began.
Zika Virus: In 2024, India reported 151 Zika virus disease cases from three states (Gujarat, Karnataka, and Maharashtra), with Maharashtra reporting the highest number since 2021. No cases of microcephaly or Guillain-Barré syndrome associated with this outbreak have been reported.
Chandipura Virus: Between June and August 2024, India reported 245 cases of Acute Encephalitis Syndrome (AES) including 82 deaths, with 64 cases confirmed as Chandipura virus. This represented the largest outbreak in 20 years, primarily affecting Gujarat and Rajasthan states.
Avian Influenza: India reported a laboratory-confirmed human case of avian influenza A(H5N1) in Karnataka in May 2025, with genome sequencing data submitted to global databases.
Public Health Response and International Measures
In response to the Nipah outbreak, several Asian countries including Thailand, Nepal and Taiwan have implemented enhanced health surveillance and travel screening. The World Health Organization (WHO) has classified Nipah as a priority pathogen requiring urgent research but does not recommend travel or trade restrictions based on current information.
Within India, the Kerala state health system—which has experienced nine Nipah outbreaks since 2018—has developed robust response protocols. During a July 2025 outbreak in Kerala, authorities identified 723 contacts across multiple districts and deployed 26 special teams for contact tracing and public awareness.
Prevention and Risk Reduction
With no vaccine available, prevention focuses on reducing exposure:
- Avoiding consumption of raw date palm sap or fruits that may be contaminated by bats
- Thoroughly washing and peeling fruits
- Wearing protective equipment when handling sick animals
- Practising good hand hygiene and avoiding close contact with infected individuals
- Implementing infection control precautions in healthcare settings
Travel and Health Advisory Context
Multiple countries including the United Kingdom, United States, Canada and Australia have issued travel health advice for India, noting risks of various infectious diseases including dengue, malaria, Zika, and now Nipah virus. General recommendations include ensuring vaccinations are up to date, practising food and water safety, and using insect bite prevention measures.
Frequently Asked Questions
How concerned should travellers to India be about Nipah virus?
For most travellers, the overall risk remains low unless there has been close exposure to an infected individual or time spent in a high-risk environment such as a healthcare setting in outbreak areas. Nipah is a rare infection with cases typically limited and localised rather than widespread.
What are the early warning signs of Nipah infection?
Early symptoms resemble common viral illnesses: fever, headache, muscle pain and fatigue. The key warning sign is when these symptoms are followed by neurological symptoms such as confusion, excessive sleepiness, seizures, or difficulty speaking, which should be treated as a medical emergency.
How does India’s current health situation compare to the COVID-19 pandemic peak?
While COVID-19 cases have resurged recently, current numbers are significantly lower than during pandemic peaks. The healthcare system is not currently reporting the severe strains seen during the Delta variant wave, though authorities remain vigilant and are conducting mock drills to ensure preparedness.
Are there any promising developments in Nipah virus treatment?
Human trials for two candidate Nipah vaccines are preparing to launch in Bangladesh. The ChAdOx1 NipahB vaccine developed at the University of Oxford recently received priority designation from the European Medicines Agency to accelerate regulatory approval. However, no approved vaccine or specific treatment is currently available.